Home/Pipeline/PCN-101 (R-ketamine)

PCN-101 (R-ketamine)

Treatment-Resistant Depression

Phase 2aActive

Key Facts

Indication

Treatment-Resistant Depression

Phase

Phase 2a

Status

Active

Company

Perception Neuroscience

About Perception Neuroscience

Perception Neuroscience, founded in 2018 and based in New York, is advancing PCN-101 (R-ketamine), a glutamatergic modulator, for treatment-resistant depression. The company's strategy is based on nonclinical data suggesting R-ketamine may offer rapid antidepressant effects with fewer dissociative side effects and lower abuse potential than S-ketamine (Spravato®). It has completed Phase 1 studies, initiated a Phase 2a proof-of-concept trial, and secured a key partnership with Otsuka Pharmaceuticals for development in Japan. Perception operates as a private, pre-revenue entity with a lean operational team and a distinguished scientific advisory board.

View full company profile

Therapeutic Areas

Psychiatry Neuroscience

Other Treatment-Resistant Depression Drugs

Drug	Company	Phase	Status
DB104 (Liafensine)	Denovo Biopharma	Phase 2b	Active
VNS Therapy for TRD	LivaNova	PMA Supplement	Active - Commercial Expansion
Precision Radiomodulation Research	ZAP Surgical	Feasibility Study	Active
NOE-101 (basimglurant)	Noema Pharma	Phase 2b	Active
mGlu2 NAM Program for TRD	Camino Pharma	Pre-clinical	Active
TAK-653	Thermo Fisher Scientific	Phase 2	Recruiting
SPN-820/821	Supernus Pharmaceuticals	Phase 3	Active
BPL-003	atai Life Sciences	Phase 2	Active
VLS-01	atai Life Sciences	Phase 2	Active